These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 25080477)

  • 1. New antigens for a multicomponent blood-stage malaria vaccine.
    Osier FH; Mackinnon MJ; Crosnier C; Fegan G; Kamuyu G; Wanaguru M; Ogada E; McDade B; Rayner JC; Wright GJ; Marsh K
    Sci Transl Med; 2014 Jul; 6(247):247ra102. PubMed ID: 25080477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya.
    Polley SD; Conway DJ; Cavanagh DR; McBride JS; Lowe BS; Williams TN; Mwangi TW; Marsh K
    Vaccine; 2006 May; 24(19):4233-46. PubMed ID: 16111789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3.
    Roussilhon C; Oeuvray C; Müller-Graf C; Tall A; Rogier C; Trape JF; Theisen M; Balde A; Pérignon JL; Druilhe P
    PLoS Med; 2007 Nov; 4(11):e320. PubMed ID: 18001147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody levels to multiple malaria vaccine candidate antigens in relation to clinical malaria episodes in children in the Kasena-Nankana district of Northern Ghana.
    Dodoo D; Atuguba F; Bosomprah S; Ansah NA; Ansah P; Lamptey H; Egyir B; Oduro AR; Gyan B; Hodgson A; Koram KA
    Malar J; 2011 May; 10():108. PubMed ID: 21529376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis.
    Fowkes FJ; Richards JS; Simpson JA; Beeson JG
    PLoS Med; 2010 Jan; 7(1):e1000218. PubMed ID: 20098724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Perraut R; Varela ML; Joos C; Diouf B; Sokhna C; Mbengue B; Tall A; Loucoubar C; Touré A; Mercereau-Puijalon O
    Vaccine; 2017 Dec; 35(48 Pt B):6720-6726. PubMed ID: 29042203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
    Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
    Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High affinity antibodies to Plasmodium falciparum merozoite antigens are associated with protection from malaria.
    Reddy SB; Anders RF; Beeson JG; Färnert A; Kironde F; Berenzon SK; Wahlgren M; Linse S; Persson KE
    PLoS One; 2012; 7(2):e32242. PubMed ID: 22363818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling the antibody immune response against blood stage malaria vaccine candidates.
    Gray JC; Corran PH; Mangia E; Gaunt MW; Li Q; Tetteh KK; Polley SD; Conway DJ; Holder AA; Bacarese-Hamilton T; Riley EM; Crisanti A
    Clin Chem; 2007 Jul; 53(7):1244-53. PubMed ID: 17510307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R; Dechavanne C; Sadissou I; d'Almeida T; Bouraima A; Sonon P; Amoussa R; Cottrell G; Le Port A; Theisen M; Remarque EJ; Longacre S; Moutairou K; Massougbodji A; Luty AJF; Nuel G; Migot-Nabias F; Sanni A; Garcia A; Milet J; Courtin D
    Malar J; 2019 Jun; 18(1):194. PubMed ID: 31185998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria.
    Polley SD; Mwangi T; Kocken CH; Thomas AW; Dutta S; Lanar DE; Remarque E; Ross A; Williams TN; Mwambingu G; Lowe B; Conway DJ; Marsh K
    Vaccine; 2004 Dec; 23(5):718-28. PubMed ID: 15542195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development.
    Richards JS; Arumugam TU; Reiling L; Healer J; Hodder AN; Fowkes FJ; Cross N; Langer C; Takeo S; Uboldi AD; Thompson JK; Gilson PR; Coppel RL; Siba PM; King CL; Torii M; Chitnis CE; Narum DL; Mueller I; Crabb BS; Cowman AF; Tsuboi T; Beeson JG
    J Immunol; 2013 Jul; 191(2):795-809. PubMed ID: 23776179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.
    Terheggen U; Drew DR; Hodder AN; Cross NJ; Mugyenyi CK; Barry AE; Anders RF; Dutta S; Osier FH; Elliott SR; Senn N; Stanisic DI; Marsh K; Siba PM; Mueller I; Richards JS; Beeson JG
    BMC Med; 2014 Oct; 12():183. PubMed ID: 25319190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.
    Osier FH; Feng G; Boyle MJ; Langer C; Zhou J; Richards JS; McCallum FJ; Reiling L; Jaworowski A; Anders RF; Marsh K; Beeson JG
    BMC Med; 2014 Jul; 12():108. PubMed ID: 24980799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
    Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
    Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).
    Kangoye DT; Nebie I; Yaro JB; Debe S; Traore S; Ouedraogo O; Sanou G; Soulama I; Diarra A; Tiono A; Marsh K; Sirima SB; Bejon P
    PLoS One; 2014; 9(9):e107965. PubMed ID: 25238160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection.
    Polley SD; Tetteh KK; Lloyd JM; Akpogheneta OJ; Greenwood BM; Bojang KA; Conway DJ
    J Infect Dis; 2007 Jan; 195(2):279-87. PubMed ID: 17191173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B; Andrew D; MacRaild CA; Morales RA; Beeson JG; Anders RF; Richards JS; Norton RS
    Sci Rep; 2016 Feb; 6():20613. PubMed ID: 26865062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.
    Osier FH; Fegan G; Polley SD; Murungi L; Verra F; Tetteh KK; Lowe B; Mwangi T; Bull PC; Thomas AW; Cavanagh DR; McBride JS; Lanar DE; Mackinnon MJ; Conway DJ; Marsh K
    Infect Immun; 2008 May; 76(5):2240-8. PubMed ID: 18316390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.